SIDT1

Across TCGA pan-cancer cohorts, SIDT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIDT1 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SIDT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIDT1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where SIDT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.220	0.767	.004	8	view →
LUAD	OS	Quartile	All	0.850	0.448	.013	4	view →
LSCC	DFS	Median	All	0.920	1.000	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SIDT1–GBM (OS)

Open the GBM breakdown →